Chapter 19. DPP-IV inhibition and therapeutic potential

Publisher Summary This chapter elaborates the dipeptidyl peptidase IV (DPP-IV) inhibition and therapeutic potential. DPP-IV's structural characteristics, proteolytic substrate requirements, and the profile of key and new inhibitors of its catalytic function are presented. With a half-life of more than 96 hours, DPP-IV is constitutively expressed by a variety of cell types, particularly on differentiated epithelial cells of the intestine, liver, prostate tissue, corpus luteum, and kidney proximal tubules as well as leukocyte subsets, such as T-helper lymphocytes and subsets of macrophages. The DPP-IV gene and its associated cDNAs from human, mouse, and rat tissue have been cloned. A single gene encoding DPP-IV has been localized to human chromosome 2 and encodes two mRNA species sized at approximately 2.8 and 4.2 kb that are present in most tissues producing DPP-IV. GLP-1 stimulates glucose-dependent insulin secretion, inhibits glucagon release, slows gastric emptying, promotes growth and differentiation of p-cells, and stimulates insulin gene expression and biosynthesis. The in vitro and in vivo studies in mice, rats, and humans have shown that DPP-IV is the primary inactivation pathway for the intestinal growth factor, GLP-2.

[1]  D. Drucker.  Glucagon-Like Peptides , 1998, Diabetes.

[2]  F. Naider,et al.  Proline-dependent structural and biological properties of peptides and proteins. , 1993, Critical reviews in biochemistry and molecular biology.

[3]  D. Drucker,et al.  New frontiers in the biology of GLP-2 , 2000, Regulatory Peptides.

[4]  C. Morimoto,et al.  Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. , 1992, Molecular immunology.

[5]  J. V. Van Beeumen,et al.  A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. , 1997, Biochimica et biophysica acta.

[6]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[7]  J. Holst,et al.  Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1. , 1999, Endocrinology.

[8]  A. Lambeir,et al.  Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. , 1999, Journal of medicinal chemistry.

[9]  M. Nauck.  Is glucagon-like peptide 1 an incretin hormone? , 1999, Diabetologia.

[10]  T. Kuribayashi,et al.  Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases. , 1991, American journal of clinical pathology.

[11]  D. Drucker,et al.  Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV , 1997, Nature Biotechnology.

[12]  I Born,et al.  Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. , 1988, Biochimica et biophysica acta.

[13]  T. Hughes,et al.  NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. , 1999, Biochemistry.

[14]  M. Hegen,et al.  Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation. , 1997, Advances in experimental medicine and biology.

[15]  B. Fleischer,et al.  Molecular analysis of CD26-mediated signal transduction in T cells. , 2000, Immunology letters.

[16]  Y. Misumi,et al.  Selective cell-surface expression of dipeptidyl peptidase IV with mutations at the active site sequence. , 1992, Biochemical and biophysical research communications.

[17]  T. Hoffmann,et al.  Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis. , 1995, Journal of chromatography. A.

[18]  E. Bosmans,et al.  Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia , 1999, British Journal of Cancer.

[19]  W. Reutter,et al.  Oligosaccharide reprocessing and recycling of a cell surface glycoprotein in cultured rat hepatocytes. , 1993, Biological chemistry Hoppe-Seyler.

[20]  Y. Misumi,et al.  Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. , 1992, Biochimica et biophysica acta.

[21]  B. Fleischer.  Dipeptidyl peptidase IV (CD26) in metabolism and immune response , 1995 .

[22]  A. Young,et al.  Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). , 1999, Diabetes.

[23]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[24]  H. Mittrücker,et al.  The T-cell receptor associated zeta-chain is required but not sufficient for CD26 (dipeptidylpeptidase IV) mediated signaling. , 1997, Immunology letters.

[25]  Y. Watanabe,et al.  Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. , 1998, Journal of biochemistry.

[26]  T. Ohnuki,et al.  Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. , 1998, Immunopharmacology.

[27]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[28]  S. J. Campbell,et al.  Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. , 1996, Journal of medicinal chemistry.

[29]  J. Blanco,et al.  Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26. , 1996, Experimental cell research.

[30]  P. Gaudreau,et al.  Catabolism of rat growth hormone-releasing factor(1–29) amide in rat serum and liver , 1992, Peptides.

[31]  A. Lambeir,et al.  In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine). , 1997, Biochemical pharmacology.

[32]  D. Marguet,et al.  Structure of the mouse dipeptidyl peptidase IV (CD26) gene. , 1994, Biochemistry.

[33]  G. Vanhoof,et al.  Decreased serum dipeptidyl peptidase IV activity in major depression , 1991, Biological Psychiatry.

[34]  J. Kupiec-Weglinski,et al.  Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. , 1997, Transplantation.

[35]  M. Szelke,et al.  4-cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV , 1996 .

[36]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.

[37]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[38]  B. O'connor,et al.  Proline specific peptidases. , 1997, Biochimica et biophysica acta.

[39]  J. Holst,et al.  Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[40]  S. J. Campbell,et al.  Inhibition of dipeptidyl peptidase IV (CD26) by peptide boronic acid dipeptides. , 1997, Journal of enzyme inhibition.

[41]  A. Schnapp,et al.  Targeted Disruption of Mouse Fibroblast Activation Protein , 2000, Molecular and Cellular Biology.

[42]  B. Klapp,et al.  Dipeptidyl peptidase IV (DPP IV, CD26) in patients with mental eating disorders. , 2000, Advances in experimental medicine and biology.

[43]  Y. Tanaka,et al.  New potent prolyl endopeptidase inhibitors: synthesis and structure-activity relationships of indan and tetralin derivatives and their analogues. , 1994, Journal of medicinal chemistry.

[44]  Garland R. Marshall,et al.  Peptides: Chemistry, Structure and Biology , 1990 .

[45]  P. Ruiz,et al.  CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma. , 1998, Cytometry.

[46]  Chika Morimoto,et al.  The structure and function of CD26 in the T‐cell immune response , 1998, Immunological reviews.

[47]  J. Holst,et al.  Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. , 2000, European journal of pharmacology.

[48]  C. Hanski,et al.  Distribution of glycosyltransferases among Golgi apparatus subfractions from liver and hepatomas of the rat. , 1991, Biochimica et biophysica acta.

[49]  A. Lambeir,et al.  Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. , 1996, Biochimica et Biophysica Acta.

[50]  M. Hegen,et al.  Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. , 1998, Molecular immunology.

[51]  M. Byrne,et al.  Glucagon-Like Peptide 1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects With Impaired Glucose Tolerance , 1998, Diabetes.

[52]  J. Holst,et al.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.

[53]  T. Hughes,et al.  1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[54]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. , 2000, Endocrinology.

[55]  P. Flatt,et al.  N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. , 2000, Biochimica et biophysica acta.

[56]  T. Nagatsu,et al.  Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. , 1991, Biochemical medicine and metabolic biology.

[57]  B. Huber,et al.  A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. , 1999, Journal of immunology.

[58]  J. Powers,et al.  Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. , 1994, Journal of medicinal chemistry.

[59]  J. Holst,et al.  Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats , 1999, Diabetologia.

[60]  J. Holst.  Gut hormones as pharmaceuticals From enteroglucagon to GLP-1 and GLP-2 , 2000, Regulatory Peptides.

[61]  Jie Zhou,et al.  Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. , 1999, Diabetes.

[62]  H. Meltzer,et al.  Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs , 1996, Acta psychiatrica Scandinavica.

[63]  T. Kubiak,et al.  In vitro metabolic degradation of a bovine growth hormone-releasing factor analog Leu27-bGRF(1-29)NH2 in bovine and porcine plasma. Correlation with plasma dipeptidylpeptidase activity. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[64]  Reutter,et al.  Alterations in Expression and in Serum Activity of Dipeptidyl Peptidase IV (DPP IV, CD26) in Patients with Hyporectic Eating Disorders , 1999, Scandinavian journal of immunology.

[65]  L. Polgár,et al.  Prolyl endopeptidase and dipeptidyl peptidase IV are distantly related members of the same family of serine proteases. , 1992, Biological chemistry Hoppe-Seyler.

[66]  I. De Meester,et al.  CD26, let it cut or cut it down. , 1999, Immunology today.

[67]  L. Bolondi,et al.  Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. , 1997, Journal of hepatology.

[68]  T. Higashijima,et al.  A potent dipeptide inhibitor of dipeptidyl peptidase IV. , 1998, Bioorganic & medicinal chemistry letters.

[69]  H. Demuth,et al.  Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. , 2000, Biochimica et biophysica acta.

[70]  W. Reutter,et al.  Modification of the intramolecular turnover of terminal carbohydrates of dipeptidylaminopeptidase IV isolated from rat-liver plasma membrane during liver regeneration. , 1984, European journal of biochemistry.

[71]  J. Rahfeld,et al.  Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? , 1991, Biochimica et biophysica acta.

[72]  A. Haemers,et al.  Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV , 1997 .

[73]  Y. Misumi,et al.  Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. , 1989, The Journal of biological chemistry.

[74]  Z. Lojda,et al.  Dipeptidyl peptidase IV in patients with systemic lupus erythematosus. , 1992, Clinical and experimental rheumatology.

[75]  Development of a tertiary-structure model of the C-terminal domain of DPP IV. , 2000, Advances in experimental medicine and biology.

[76]  U. Lendeckel,et al.  Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). , 1999, International journal of molecular medicine.

[77]  T. Steinmetzer,et al.  Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. , 1991, Biological chemistry Hoppe-Seyler.

[78]  U. Günther,et al.  Solution structures of active and inactive forms of the DP IV (CD26) inhibitor Pro-boroPro determined by NMR spectroscopy. , 1994, Biochemistry.

[79]  Y. Koiso,et al.  Novel small molecule nonpeptide aminopeptidase n inhibitors with a cyclic imide skeleton. , 1999, Journal of enzyme inhibition.

[80]  G. Fischer,et al.  The conformation around the peptide bond between the P1- and P2-positions is important for catalytic activity of some proline-specific proteases. , 1983, Biochimica et biophysica acta.

[81]  W. Bachovchin,et al.  Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. , 1993, Biochemistry.

[82]  K. Kuma,et al.  Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of ‘benign’ thyroid tumor , 1999, Pathology international.

[83]  Paul D. Jenkins,et al.  2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV , 1996 .

[84]  I. Ohkubo,et al.  Dipeptidyl peptidase II from porcine seminal plasma: purification, characterization, and its homology to granzymes, cytotoxic cell proteinases (CCP 1-4). , 1996, Biochimica et Biophysica Acta.

[85]  D. Marguet,et al.  cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. , 1992, The Journal of biological chemistry.

[86]  G. Rassner,et al.  Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study , 1995, Journal of cutaneous pathology.

[87]  C. Durinx,et al.  The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. , 1999, Current medicinal chemistry.

[88]  Y. Asai,et al.  TMC-2A, -2B and -2C, new dipeptidyl peptidase IV inhibitors produced by Aspergillus oryzae A374. II. Isolation and structure determination. , 1997, The Journal of antibiotics.

[89]  J. Blanco,et al.  Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. , 1996, European journal of biochemistry.

[90]  N. Thompson,et al.  A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model. , 1991, The Biochemical journal.

[91]  S. Mathieu,et al.  Homodimerization via a leucine zipper motif is required for enzymatic activity of quiescent cell proline dipeptidase. , 2000, The Journal of biological chemistry.

[92]  J. Holst,et al.  In vivo and in vitro degradation of glucagon-like peptide-2 in humans. , 2000, The Journal of clinical endocrinology and metabolism.

[93]  R. Pederson,et al.  Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. , 1999, Metabolism: clinical and experimental.

[94]  A. Houghton,et al.  A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase , 1993, The Journal of experimental medicine.

[95]  A. Houghton,et al.  A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells , 1999, The Journal of experimental medicine.

[96]  J Li,et al.  Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). , 1995, Archives of biochemistry and biophysics.

[97]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[98]  M. Nauck.  Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective , 1998, Acta Diabetologica.

[99]  W. Brandt,et al.  A new mechanism in serine proteases catalysis exhibited by dipeptidyl peptidase IV (DP IV)--Results of PM3 semiempirical thermodynamic studies supported by experimental results. , 1996, European journal of biochemistry.

[100]  M. Schutkowski,et al.  Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. , 1991, Biological chemistry Hoppe-Seyler.

[101]  J. Gitlin,et al.  Tissue-specific regulation of dipeptidyl peptidase IV expression during development. , 1991, The Biochemical journal.

[102]  A. Schnapp,et al.  Mouse fibroblast‐activation protein , 1998 .

[103]  G. Sutherland,et al.  Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. , 2000, European journal of biochemistry.

[104]  J. Blanco,et al.  Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26. , 1998, Journal of medicinal chemistry.

[105]  N. Ozmeric,et al.  Alanine aminopeptidase and dipeptidylpeptidase IV in saliva: the possible role in periodontal disease. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[106]  C. Maryanoff,et al.  Advances in medicinal chemistry , 1992 .

[107]  J. Faust,et al.  Potent inhibitors of dipeptidyl peptidase IV and their mechanisms of inhibition. , 2000, Advances in experimental medicine and biology.

[108]  G. Vriend,et al.  The purification, characterization and analysis of primary and secondary-structure of prolyl oligopeptidase from human lymphocytes. Evidence that the enzyme belongs to the alpha/beta hydrolase fold family. , 1995, European journal of biochemistry.

[109]  C. Lluis,et al.  Enzymatic and extraenzymatic role of ecto‐adenosine deaminase in lymphocytes , 1998, Immunological reviews.

[110]  D. Cassio,et al.  Establishment of hepatic cell polarity in the rat hepatoma-human fibroblast hybrid WIF-B9. A biphasic phenomenon going from a simple epithelial polarized phenotype to an hepatic polarized one. , 1996, Journal of cell science.

[111]  A. Harris,et al.  Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. , 1994, Journal of clinical pathology.

[112]  N. Katunuma,et al.  Comparative studies of the sugar chains of aminopeptidase N and dipeptidylpeptidase IV purified from rat kidney brush-border membrane. , 1988, Biochemistry.

[113]  Y. Asai,et al.  TMC-2A, -2B and -2C, novel dipeptidyl peptidase IV inhibitors produced by Aspergillus oryzae A374. I. Taxonomy of producing strain, fermentation, and biochemical properties. , 1997, The Journal of antibiotics.